This past Sunday was the second day of the American Society of Hema­tology’s (ASH) annual meeting, which was held in San Francisco.

As on the first day of the meeting, myeloma-related pre­sen­ta­tions once again took place during several sessions through­out the day.

A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.

While the education session was being held, a separate “scientific sym­po­sium” with two oral pre­sen­ta­tions took place in parallel.  The session focused on a novel immuno­therapeutic ap­proach to treating cancer known as …

The 2014 annual meeting of the American Society of He­ma­tol­ogy (ASH) starts tomorrow, De­cem­ber 5, in San Francisco, and will con­tinue until next Tuesday.

The ASH annual meeting is one of sev­er­al large med­i­cal conferences where myeloma-related re­search findings are pre­sented each year.  However, from a mul­ti­ple myeloma perspective, the ASH meeting is generally the most im­por­tant of the meetings.

At this year’s meeting, for example, some 500 myeloma-presentations are scheduled to take place.  The pre­sen­ta­tions will summarize cur­rent re­search on a wide range of topics, in­clud­ing the biology of the dis­ease …

• First study of dara­tu­mu­mab in smoldering multiple myeloma
• Study expected to start in  2015

Copenhagen, Denmark (Press Release) - Genmab A/S (OMX: GEN) announced today that its col­lab­o­ra­tion partner, Janssen Biotech, Inc. (Janssen) plans to start a Phase II study of dara­tu­mu­mab in smol­der­ing multiple myeloma.  The study (SMM2001) will eval­u­ate three dif­fer­en­t dose schedules of dara­tu­mu­mab for the treat­ment of smol­der­ing multiple myeloma.  The study is ex­pec­ted to start enrolling patients in 2015.

"We are pleased to announce this study, which illustrates that the devel­op­ment plan for dara­tu­mu­mab encompasses all stages of multiple myeloma. …

It’s July, and we have had some time to digest the findings from the American Society of Clinical Oncology (ASCO) annual meeting held in Chicago May 30 through June 3.

Quite a few pre­sen­ta­tions caught one’s eye.

We finally saw the results of the much awaited PANORAMA-1 study in­ves­ti­gating the efficacy and safety of panobinostat (LBH589) plus Velcade and dexa­meth­a­sone com­pared to Velcade and dexa­meth­a­sone alone.

Exciting data on the CD38 anti­bodies daratumumab and SAR650984 continued to emerge at ASCO.

Another study looked at a pro­gres­sion-free …

This year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago came to an end yesterday.

The fourth day of the meeting, which was Monday, was the busiest day in regard to myeloma-related re­search. It started with an oral pre­sen­ta­tion session that in­cluded seven talks about im­por­tant new myeloma-related re­search. A poster session in the afternoon in­cluded several posters about myeloma-related re­search.

This article summarizes the most im­por­tant findings from Monday’s oral pre­sen­ta­tion session. A later article will cover the findings from the after­noon poster session.

The morning session …

This year’s American Society of Clinical Oncology (ASCO) annual meeting began yester­day morning in Chicago and will run through Tuesday.

Myeloma-related pre­sen­ta­tions were made during two sessions yes­ter­day.

One session was designed to better educate physicians about per­son­al­ized ther­apy for elderly patients with lymphoid malig­nan­cies. During that session, Dr. Tanya Marya Wildes from the Washington University School of Medicine in St. Louis talked about how to navigate treat­ment options for older multiple myeloma patients.

The key myeloma-related re­search pre­sented yesterday was made public during a poster session in the afternoon about studies …

The American Society of Clinical Oncology will hold its 50^th annual meet­ing May 30 through June 3 in Chicago.

Similar to pre­vi­ous years, more than 25,000 physicians and re­searchers from all over the world are ex­pec­ted to attend the five-day meeting to dis­cuss the current re­search in cancer treat­ment and care.

During the meeting, there will be pre­sen­ta­tions about all areas of cancer, in­clud­ing many focused specifically on multiple myeloma. The ASCO website cur­rently lists in­for­ma­tion about more than 60 myeloma-related studies (included under either the "multiple myeloma" or "plasma cell …